Perspective Therapeutics, Inc. (CATX)
Perspective Therapeutics develops cancer drugs that deliver targeted radiation to tumors, paired with imaging tools to guide treatment. It last closed at $0.86 on Nov 17, down 9.11% on the day. The average 12-month price target from 4 analysts is $6.75 (+685.9% from the last close), with a high of $8.00 and a low of $4.00. Analyst consensus is Strong Buy, based on the latest ratings from 4 firms (3 buy, 1 hold, 0 sell). In the past 30 days there were 1 dark pool print totaling $116K, the largest $116K.
Key Stats
Last 12 monthsNot reported for this period.
From CATX's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 9). Last 12 months adds up the four latest quarters.
Earnings
Full earnings history →Analyst Ratings & Price Targets
Analyst Ratings →Based on 4 analysts who set a price target on CATX in the past 90 days. The average target is $6.75, with a high of $8.00 and a low of $4.00, compared with the last close of $0.86.
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Nov 10 | Truist Securities | Maintained | Buy | $8 |
| Nov 10 | Wedbush | Target lowered | Buy | $11 → $7 |
| Nov 10 | Piper Sandler | Target lowered | Buy | $14 → $8 |
| Oct 26 | RBC Capital | Downgrade | Hold | $4 |
| Sep 15 | Wedbush | Reiterated | Buy | $11 |
Technical Analysis
The stock is 32% below its 20 day and 135% below its 50 day average. It is 297% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 28), oversold. The nearest support is the Pivot S1 at $0.80, and the nearest resistance the Pivot at $0.87.
| RSI (14) | 27.81 | Oversold below 30 | Oversold |
| MACD | -0.36 | Above its signal line | Bullish |
| Stochastic | 27.9 | Middle of its range | Neutral |
| ADX (14) | 50.6 | Strong downtrend | |
| Williams %R | -83.9 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -59.2 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | −2.0% | Change over 10 sessions | Bearish |
| ATR (14) | $0.16 | Typical daily range, 18.4% of price |
| RSI (14) | 25.42 | Oversold below 30 | Oversold |
| MACD | -0.65 | Below its signal line | Bearish |
| Stochastic | 3.6 | Near the bottom of its range | Oversold |
| ADX (14) | 23.2 | Weak trend | |
| Williams %R | -97.2 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -157.7 | Oversold below −100, overbought above 100 | Oversold |
| Rate of change | −69.4% | Change over 10 sessions | Bearish |
| ATR (14) | $0.47 | Typical daily range, 55.2% of price |
What happened before
See how CATX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How CATX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2006.
Whale Options Flow
90DNo whale options trades in CATX in the last 90 days.
Dark Pool
30DCATX Institutional Ownership
Full report →- ●58 buying vs 59 selling
- ▼Held by funds -7.8 pts
- ▼Funds holding -12
- ▲Superinvestors: 4 added, 0 cut
- ●Put/call not meaningful
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 120 | 132 | −9.1% |
| In funds' top 10 | 3 | 3 | 0.0% |
| Held by funds | 66.3% | 74.2% | −7.8 pts |
| New / increased | 14 / 44 | 23 / 59 | −29.3% |
| Reduced / sold out | 35 / 24 | 27 / 30 | +3.5% |
| Put/call ratio | – | – | – |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether CATX is in one of them and how their past CATX trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered CATX in an article yet. Here's the latest on the wider market.
About Perspective Therapeutics
Perspective Therapeutics is a radiopharmaceutical development company based in Seattle, Washington. It is developing cancer treatments that attach a radioactive isotope known as lead 212 to targeting molecules, which are designed to carry radiation directly to cancer cells. The company also develops imaging agents using a related isotope so that doctors can locate tumors before treatment. Its lead candidates are in clinical trials in the United States for neuroendocrine tumors, melanoma and other solid tumors. The intended users of these treatments are cancer patients and the clinicians who treat them, and the company is building its own manufacturing capacity.
- Headquarters
- Seattle, WA



